Standout Papers

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial 2025 202632
  1. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial (2025)
    Armin Ghobadi, Veronika Bachanová et al. The Lancet

Immediate Impact

3 by Nobel laureates 17 from Science/Nature 58 standout
Sub-graph 1 of 22

Citing Papers

Natural killer cell therapies
2024 StandoutNature
A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells
2024 Standout
4 intermediate papers

Works of Lilly Wong being referenced

Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma
2021
First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
2020

Author Peers

Author Last Decade Papers Cites
Lilly Wong 576 315 198 46 1000
Maciej Wieczorek 793 236 238 80 1.3k
Chih-Min Kam 675 358 272 35 1.3k
Xiaoling Xie 378 172 226 55 1.1k
Joakim E. Swedberg 990 193 109 44 1.3k
Simon J. de Veer 909 170 137 50 1.3k
Raghavendra Gowda 682 245 164 36 1.2k
Bainan Wu 865 244 101 28 1.2k
K. Heide 588 103 146 48 1.2k
Yuyin Li 602 274 127 49 942
Martin Schröder 655 281 129 44 1.2k

All Works

Loading papers...

Rankless by CCL
2026